1. Clin Infect Dis. 2012 Apr;54 Suppl 3:S229-32.

Macrophage killing of bacterial and fungal pathogens is not inhibited by intense 
intracellular accumulation of the lipoglycopeptide antibiotic oritavancin.

Baquir B, Lemaire S, Van Bambeke F, Tulkens PM, Lin L, Spellberg B.

Division of General Internal Medicine, Los Angeles Biomedical Research Institute 
at Harbor-University of California at Los Angeles (UCLA) Medical Center.

Intact phagocytic effector function is fundamental to host defense against
microbial pathogens. Concern has been raised regarding the potential that
accumulation of certain agents, including cationic amphiphilic antibiotics,
within macrophages could cause a mixed-lipid storage disorder, resulting in
macrophage dysfunction in recipients. The ability of 2 macrophage cell lines
(HL-60; RAW 264.7) to kill archetypal Gram-positive (Staphylococcus aureus),
Gram-negative (Acinetobacter baumannii), and fungal (Candida albicans) pathogens 
was tested following exposure of the macrophages to the lipoglycopeptide
antibiotic oritavancin. Oritavancin did not affect killing of C. albicans but
markedly enhanced killing of S. aureus by both macrophages. Oritavancin modestly 
reduced killing of A. baumannii by HL-60 cells but not by RAW 264.7 cells. Thus, 
macrophage killing of microbes remains intact despite substantial intracellular
accumulation with a lipoglycopeptide antibiotic.

PMCID: PMC3307583 [Available on 2013/4/15]
PMID: 22431853  [PubMed - in process]